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Background
▪ Stress-hyperglycaemia is a common complication in the ICU.
▪ Glycaemic control (GC) has shown improved outcomes but was
proven difficult to achieve safely, increasing risks of hypoglycaemia.
▪ STAR is a model-based GC protocol with proven safety and
performance. It uses a unique risk-based dosing approach
accounting for both intra- and inter- patient variability.
▪ STAR determines the best insulin and nutrition treatment option by
assessing the likelihood of future metabolic variability based on
current identified insulin sensitivity, as depicted in Figure 1.
Figure 1 – Future insulin sensitivity (SI) is forecast from current SI. The distribution of future SI is used to predict likely BG outcomes for a given 
insulin-nutrition treatment intervention.
Objectives
▪ Most GC design uses insulin-only intervention while STAR uses
both insulin and nutrition.
▪ This study uses an insulin only version of STAR with nutrition set
clinically in the University Hospital of Liège, Belgium, to assess
safety and efficacy in this use.
Methods
Ethics approval was granted by the University Hospital of Liège Ethics
Committee for the STAR-Liège clinical trial. STAR-Liège offers 1-3
hourly blood glucose (BG) measurements options. Insulin is
administered through IV catheter continuously and nutrition clinically
set.
▪ Target band: 4.4-8.0 mmol/L (80-145 mg/dL)
▪ Starting criteria: 2 BG measurements > 8.0 mmol/L (145 mg/dL)
▪ Stopping criteria: BG stable for 6h at low insulin rates (≤ 2U/h) or
72h after inclusion.
















▪ BG traces from clinical data are shown in Figure 2 and results are
shown in Table 1.
Figure 2 – BG traces over time for the first 11 patients included in the STAR-Liège clinical trial.
Table 1 – Clinical data from 11 STAR-Liège patients. Results are given as median [IQR].
▪ High performance: median [IQR] BG of 6.7 [5.9 7.7] mmol/L (122
[106 147] mg/dL) and 78% BG in band.
▪ High safety: only 1% BG < 4.4 mmol/L (80 mg/dL), no incidence of
severe hypoglycaemia (BG < 40 mg/dL or 2.2 mmol/L), and 10% of
BG > 180mg/dL (10.0 mmol/L).
▪ High compliance: only 14% of intervention changed by clinical staff.
→ High safety and efficacy for nearly all patients!
Conclusions
▪ Insulin-only GC with the STAR-Liège protocol succeeds in
providing equally high safety and quality for nearly all patients.
▪ Failed to reduce BG in 1 consistently highly resistant patient.
Reducing nutritional input as per the original STAR design could
reduce BG to safer range for this patient.
▪ These results are encouraging, comparable to previous studies,
and support STAR’s risk-based dosing approach as a robust
solution across different ICU settings and usages.
STAR is fully computerised and implemented on a
tablet running Android. Nurses are free to choose
any possible treatment option (1-3 hourly).
Results from the first 11 patients are analysed.
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Total hours of control 645
Workload (#measurements/day) 16
Median BG (mmol/L) 6.7 [5.9 7.7]
Insulin rate (U/h) 3.5 [1.5 6.0]
Nutrition (dextrose) rate (g/h) 8.1 [4.9 9.2]
%BG within 4.4-8.0 mmol/L (80-145 mg/dL) 78
%BG > 10.0 mmol/L (180 mg/dL) 10
%BG <4.4 mmol/L (80 mg/dL) 1
%BG <2.2 mmol/L (40 mg/dL) 0
Unchanged intervention (%) 86
